

Supplemental Table S1. Primers used for quantitative RT-PCR.

mRNA	Forward	Reverse	Genbank/EMBL Accession no.	Nucleotide no.
<i>PTGS2/ COX-2</i>	5'-TGTGCAACACTTGAGTGG CT-3'	5'-ACTTTCTGTACTGCGGGTGG-3'	AY151286	1381-1677
<i>PTGES/ mPGES-1</i>	5'-TCTTAGCCCCTTGATTCT-3'	5'-ATTCTTAGCCCGGGATTGAG-3'	BC008280	695-898
<i>GAPDH</i>	5'-TGATGACATCAAGAAGGTGGTGAAG-3'	5'-TCCTTGGAGGCCATGTAGGCCAT-3'	BC014085	1644-1883

Supplemental Table S2. Demographic characteristics of the pregnancies used in the DNA methylome study using MeDIP.


Study group	(a) TL (n = 11)	(b) TNL-s (n = 10)	(c) TNL-l (n = 9)	(d) PTNL (n = 10)	(e) iPTL (n = 6)	(f) tPTL (n = 7)
Maternal age (yrs)	34.7 ± 4.0 (28; 41)	27.8 ± 4.3 (22; 35)	32.8 ± 2.7 (27; 36)	33.2 ± 6.0 (24; 40)	32.8 ± 6.7 (23; 40)	34.6 ± 11.1 (20; 55)
Parity	0.7 ± 0.5 (0; 1)	1.4 ± 0.7 (0; 2)	0.7 ± 0.5 (0; 1)	0.7 ± 0.8 (0; 2)	1.0 ± 1.3 (0; 3)	0.1 ± 0.4 (0; 1) ^a
Maternal BMI (kg/m ²)	23.9 ± 3.0 (20; 29) ^a	32.0 ± 4.4 (25; 41)	25.0 ± 8.5 (19; 45)	25.7 ± 6.5 (19; 35)	23.8 ± 4.1 (19; 29)	24.3 ± 6.3 (18; 35)
No. of women smoking during pregnancy	0	0	0	0 ^c	0 ^d	0
Race/Ethnicity	White (6) ^e Black (2) Asian (1)	Hispanic White (8) Non-Hispanic White (1) Asian (1)	White (5) ^f Black (1)	White (5) ^c Black (2) Pakistani (1)	White (5) ^d	White (6) ^f
Birth weight (g)	3360 ± 373 (2670; 3990)	3316 ± 268 (2987; 3731)	3612 ± 357 (3070; 4280)	1966 ± 544 (1225; 3110) ^b	2403 ± 462 (2090; 3160) ^b	2072 ± 486 (1523; 2855) ^b
No. of boys/girls	7/4	6/4	6/3	4/6	2/4	9/5
IUGR (< 2500 g)	0	0	0	9	4	5
Macrosomia (≥ 4000 g)	0	0	1	0	0	0

Data are given as mean ± SD with range in parentheses, except where indicated differently. ^a*p<0.05 vs TNL-s group with one-way ANOVA followed by Bonferroni's post-hoc comparisons tests. ^b**p<0.01 vs. TL, TNL-s and TNL-l. ^{c,d,e,f}Data of 8, 5, 9 and 6 pregnancies.

Supplemental Table S3. Control gene methylation detected in the human myometrium.

Positive controls	Locus	Cytosine methylation	CpG island	Peak score [#]
<i>TSH2B</i> (<i>HIST1H2BA</i>) [§]	6p22.2	Detected	5'	4.63 ± 0.46 (4.22; 5.41)
<i>H1T</i> (<i>HIST1H1T</i>) [§]	6p21.3	Detected	5'	3.39 ± 0.30 (3.12; 3.89)
<i>PRM1</i> (protamine 1)	16p13.2	Detected	3'	3.23 ± 0.37 (2.83; 3.75)
Negative controls				
<i>GAPDH</i>	12p13.31	Not detected	5'	N/A
<i>HIST1H1E</i>	6p21.3	Not detected	5'	N/A
<i>HIST1H2AC</i>	6p22.1	Not detected	5'	N/A

[#]Data are given as mean ± SD with range in parentheses. N/A, not applicable. [§]Testis-specific histone variants that are expressed exclusively in testis. The CpG sites of these histone variant genes are methylated in somatic cells but not in testis.



Supplemental Figure S1. (A) Selective enrichment of methylated DNA fragments in the MeDIP preparation. The whole genome-amplified products from immunoprecipitated and non-immunoprecipitated (input) DNA fragments were subjected to PCR amplification with primer pairs specific to the *GAPDH* and *TSH2B* genomic regions. The region amplified with the *TSH2B* primer pair corresponds to genomic locus that is unmethylated in testis and highly methylated in all somatic cells tested and was used as a control gene representing inactive methylated regions. *GAPDH* primer pair is designed from the constitutively active promoter region and used as an unmethylated negative control gene. Preferential amplification was detected for the unmethylated *GAPDH* promoter region in the input DNA and for the methylated *TSH2B* promoter region in the MeDIP DNA preparations. The expected products for the *GAPDH* and *TSH2B* primer pairs from genomic DNA template are 88 bp and 170 bp, respectively. A 100 bp ladder was used as a DNA size marker (lane S). No amplification was detected in the no template controls (NTC). Untreated genomic DNA samples were used as a positive control template in the PCR amplification assays. (B) Cytosine methylation at the positive control gene *TSH2B* was readily detected in the human myometrium methylome using MeDIP-chip analysis. Statistically significant p-values were determined by 750 bp sliding window analysis.